Numinus Wellness Inc. Provides Corporate Update

Cookie Settings We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use . Necessary Analytics Accept All Accept Selection Reject All × Skip to main content Newsfile Search English Français Deutsch Español Search × Login Username Password Login Newsfile Login Search Français Home About About Company Overview Who We Serve Upcoming Events Careers Services Services Press Release Distribution News Service Overview Global Distribution Additional News Services AI Disclosure Intelligence SEDAR+ About SEDAR+ SEDAR+ Resources EDGAR EDGAR Service Overview EDGAR Resources Webcasting and Conference Calling Newsroom Newsroom Newsroom Newswire Guidelines Sign Up for News Integrate Blog Contact Numinus Wellness Inc. Provides Corporate Update All financial results are reported in Canadian dollars unless otherwise stated. September 01, 2026 5:39 AM EDT | Source: Numinus Wellness Inc. Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Numinus Wellness Inc. (OTC Pink: NUMIF) (" Numinus " or the " Company ") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced that it has filed all quarterly interim financial reports for fiscal year 2026 to May 31, 2026. With the recent completion of the August 31, 2025, audit, together with the filings of the Company's outstanding interim financial reports for fiscal year 2026, the Company is positioned to satisfy the regulatory requirements necessary for the British Columbia Securities Commission (the "BCSC") to have the current cease trade order (the "CTO") with respect to the Company revoked. Concurrently, management shall continue with its previously announced application to list its common shares on the Canadian Securities Exchange (the "CSE"). Successfully executing these steps remains management's primary strategy to restore trading, enhance shareholder liquidity, and position the Company for its next phase of growth. A listing on the CSE will be contingent on the Company satisfying the CSE's listing requirements and being approved for the listing on that exchange Q3 Fiscal 2026 Highlights Revenue of $4.5 million for the period ending Q3 2026 Gross profit of $0.9M compared to a gross profit of $0.9 million in Q2 2026 Gross margin of 54.4% compared to a gross margin of 55.9% during Q2 2026 Cash position of $0.5 million as of May 31, 2026 Profit of $0.8 million in the Company's Practitioner Training segment as of Q3 2026 Results from Continuing Operations for Q3 Fiscal 2026 Consolidated revenue was substantially unchanged quarter over quarter, decreasing 0.5% from Q2 2026. Revenue from Cedar Clinical Research ("CCR") increased 29.0%, from $0.9 million in Q2 2026 to $1.2 million in Q3 2026, reflecting a recovery from seasonal variation in clinical trial patient visits. Revenue from Practitioner Training decreased from $0.7 million in Q2 2026 to $0.4 million in Q3 2026. The decrease reflects the number of participants trained in the period under existing training contracts rather than a reduction in contracted work. The Practitioner Training segment recorded segment profit of $0.8 million for the nine months ended May 31, 2026 and has been profitable in each quarter since August 31, 2025. Balance Sheet and Liquidity Numinus ended the quarter with cash and cash equivalents of $0.5 million and a working capital deficiency of $3.8 million. Q3 2026 Performance Metrics For the quarter ended: May 31, 2026 (Q3 2026) February 28, 2026 (Q2 2026) % change Total Revenue $1,607,738 $1,616,064 -0.5% Cost of revenue 733,417 712,960 2.9% Gross Profit (Loss) $874,321 $903,104 -3.2% Gross profit margin (loss) 54.4% 55.9% -270 bps Operating expenses and other items 1,131,401 1,048,194 7.9% Loss and comprehensive loss ($314,434) ($161,636) n/a Numinus' consolidated financial statements for the year ended August 31, 2025 and for the interim periods ended November 30, 2026, February 28, 2026 and May 31, 2026, and related management's discussion and analysis are available on Numinus' Investor Relations website at www.investors.numinusnetwork.com and under the Company's profile on SEDAR+ at www.sedarplus.ca . These documents were prepared in accordance with IFRS. About Numinus Numinus Wellness Inc. (OTC Pink: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic research and training - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. Learn more at www.numinusnetwork.com and follow us on LinkedI